Rare Diseases: Drug Discovery and Informatics Resource (Q45873887)

http://europepmc.org/abstract/MED/29094320

17 December 2017

title

Rare Diseases: Drug Discovery and Informatics Resource (English)

1 reference

http://europepmc.org/abstract/MED/29094320

17 December 2017

1 reference

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29094320%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

author name string

Mingzhu Zhao

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29094320%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

publication date

1 November 2017

1 reference

http://europepmc.org/abstract/MED/29094320

17 December 2017

published in

Interdisciplinary sciences, computational life sciences

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29094320%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29094320%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

page(s)

195-204

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29094320%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29094320%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s12539-017-0270-3

7 June 2020

exact match

0 references

cites work

Defining rare diseases in China

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Challenges in orphan drug development and regulatory policy in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Drug repositioning for orphan diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Gene therapy returns to centre stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Gene therapy: Industrial strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Allogeneic cellular gene therapy in hemoglobinopathies--evaluation of hematopoietic SCT in sickle cell anemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Gene therapy for sickle cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Self-complementary AAV-mediated gene therapy restores cone function and prevents cone degeneration in two models of Rpe65 deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Improvement and decline in vision with gene therapy in childhood blindness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Developing gene and cell therapies for rare diseases: an opportunity for synergy between academia and industry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Normoglycemia alone is insufficient to prevent long-term complications of hepatocellular adenoma in glycogen storage disease type Ib mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Recent advances in gene therapy for lysosomal storage disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Targeted high-efficiency, homogeneous myocardial gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Overcoming Gene-Delivery Hurdles: Physiological Considerations for Nonviral Vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

The heart in Anderson-Fabry disease and other lysosomal storage disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

The management and treatment of children with Fabry disease: A United States-based perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

The attenuated/late onset lysosomal storage disorders: Therapeutic goals and indications for enzyme replacement treatment in Gaucher and Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Anderson-Fabry disease and other lysosomal storage disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Treatment of lysosomal storage diseases: recent patents and future strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Gene therapy for immunodeficiency due to adenosine deaminase deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Hypophosphatasia: Enzyme Replacement Therapy Brings New Opportunities and New Challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Fabry_CEP: a tool to identify Fabry mutations responsive to pharmacological chaperones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Rational approaches to targeted polypharmacology: creating and navigating protein-ligand interaction networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Drug repositioning can accelerate discovery of pharmacological chaperones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Unveiling the role of network and systems biology in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Representation of rare diseases in health information systems: the Orphanet approach to serve a wide range of end users

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

RAMEDIS: a comprehensive information system for variations and corresponding phenotypes of rare metabolic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

FORGE Canada Consortium: outcomes of a 2-year national rare-disease gene-discovery project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Identification of small molecules enhancing autophagic function from drug network analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Drug repositioning for orphan genetic diseases through Conserved Anticoexpressed Gene Clusters (CAGCs)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

The Human Phenotype Ontology: a tool for annotating and analyzing human hereditary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

PhenomeCentral: a portal for phenotypic and genotypic matchmaking of patients with rare genetic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

DECIPHER: web-based, community resource for clinical interpretation of rare variants in developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

The TREAT-NMD care and trial site registry: an online registry to facilitate clinical research for neuromuscular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Implementation of a population-based epidemiological rare disease registry: study protocol of the amyotrophic lateral sclerosis (ALS)--registry Swabia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Early stages of building a rare disease registry, methods and 2010 data from the Belgian Neuromuscular Disease Registry (BNMDR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

If you build a rare disease registry, will they enroll and will they use it? Methods and data from the National Registry of Myotonic Dystrophy (DM) and Facioscapulohumeral Muscular Dystrophy (FSHD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

NIH/NCATS/GRDR® Common Data Elements: A leading force for standardized data collection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Innovative measures to combat rare diseases in China: The national rare diseases registry system, larger-scale clinical cohort studies, and studies in combination with precision medicine research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Computational and experimental advances in drug repositioning for accelerated therapeutic stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Relating protein pharmacology by ligand chemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Predicting new molecular targets for known drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Prediction and evaluation of protein farnesyltransferase inhibition by commercial drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Large-scale prediction and testing of drug activity on side-effect targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

A pharmacological organization of G protein-coupled receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Combinatorial computational method gives new picomolar ligands for a known enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Conformational changes of G protein-coupled receptors during their activation by agonist binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Ligand-protein inverse docking and its potential use in the computer search of protein targets of a small molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Prediction of potential toxicity and side effect protein targets of a small molecule by a ligand-protein inverse docking approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Inverse in silico screening for identification of kinase inhibitor targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Identifying off-target effects and hidden phenotypes of drugs in human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Incorporation of protein flexibility and conformational energy penalties in docking screens to improve ligand discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Mining significant substructure pairs for interpreting polypharmacology in drug-target network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

The α7 nAChR selective agonists as drug candidates for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Multi-algorithm and multi-model based drug target prediction and web server

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Exploring off-targets and off-systems for adverse drug reactions via chemical-protein interactome--clozapine-induced agranulocytosis as a case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

TarFisDock: a web server for identifying drug targets with docking approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

ChemMapper: a versatile web server for exploring pharmacology and chemical structure association based on molecular 3D similarity method.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

The topology of drug-target interaction networks: implicit dependence on drug properties and target families

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Prediction of drug-target interactions and drug repositioning via network-based inference

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Predicting drug targets based on protein domains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Drug-domain interaction networks in myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Drug target identification using side-effect similarity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Systematic evaluation of drug-disease relationships to identify leads for novel drug uses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Drug repositioning based on comprehensive similarity measures and Bi-Random walk algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Scoring multiple features to predict drug disease associations using information fusion and aggregation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Kinetic modelling of NSAID action on COX-1: focus on in vitro/in vivo aspects and drug combinations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Modeling of the bacterial mechanism of methicillin-resistance by a systems biology approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Drug repositioning framework by incorporating functional information

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Pathway-based Bayesian inference of drug-disease interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Molecular networks for the study of TCM pharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Network-based global inference of human disease genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Modularity-based credible prediction of disease genes and detection of disease subtypes on the phenotype-gene heterogeneous network.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

A CTD-Pfizer collaboration: manual curation of 88,000 scientific articles text mined for drug-disease and drug-phenotype interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

A network-based classification model for deriving novel drug-disease associations and assessing their molecular actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Disease Ontology: a backbone for disease semantic integration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

DrugNet: network-based drug-disease prioritization by integrating heterogeneous data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Systems biology brings new dimensions for structure-based drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Network-based drug repositioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Exploring the ligand-protein networks in traditional chinese medicine: current databases, methods, and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3

Use of genome-wide association studies for drug repositioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12539-017-0270-3